Fedratinib improves OS and PFS for patients with myelofibrosis as first-line therapy and after ruxolitinib
Fedratinib is an oral JAK2 inhibitor that improves splenomegaly and symptoms in patients with intermediate or high-risk myelofibrosis – as first-line (1L) treatment or after ruxolitinib-treatment. In this MEDtalk, Claire Harrison, professor of myeloproliferative neoplasms, presents the survival outcomes from the JAKARTA and JAKARTA2 trial.
